Neurology

Cranial neuropathies and COVID-19: Neurotropism and autoimmunity


The coronavirus disease 2019 (COVID-19) global pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. Like its predecessors, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 binds to angiotensin converting enzyme 2 (ACE2) receptors to facilitate tissue invasion and potentially gain entry into the nervous system.1 This single-stranded RNA virus shares 75%–80% identical genome sequence with MERS-CoV and SARS-CoV, but has increased virulence, persistence, and lethality.2 Amid catastrophic human suffering, severe neurologic complications of COVID-19 have been identified, yet subtle neurologic manifestations likely have been underreported.

Source link

Related posts

The Reality of Living Through A Flare

Newsemia

Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathies

Newsemia

Medical Marijuana in Texas: Dr. Keough Updates on Compassionate Use Program

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World